The initiative will establish the first proton therapy programme within Türkiye's private healthcare sector, further strengthening Acibadem's advanced oncology capabilities.

As one of Türkiye's leading healthcare providers, Acibadem combines a broad network of hospitals and medical centres with the academic and research expertise of Acibadem University. The addition of proton therapy will enhance the Group's ability to offer precision treatment options for patients with complex cancers, complementing its existing strengths in surgical, medical, paediatric and radiation oncology.

Proton therapy is an advanced form of radiation treatment that enables highly targeted tumour irradiation while minimising exposure to surrounding healthy tissue. It is particularly beneficial for selected cancers where reducing radiation-related side effects is critical.

The programme will also support the development of specialised oncology expertise through collaboration with Acibadem University, helping to advance clinical training and knowledge sharing across the region.

The investment reflects Acibadem's continued focus on bringing innovative medical technologies and multidisciplinary expertise together to improve patient outcomes and expand access to advanced cancer care. As part of IHH Healthcare's global network, Acibadem continues to strengthen its role in delivering world-class, patient-centred care across the region.